Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 858

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 858
---
 as set out in IFRS9, the embedded derivative must be separated from the host contract by measuring the fair value of the embedded derivative and allocating the remaining consideration to the host contract. The embedded derivative component shall be measured at fair value each reporting period, and changes shall be recognized in profit or loss (hereinafter, “Fair Value Through Profit or Loss”). Consequently, at the initial recognition of the convertible loan, the Company measured the fair value of the conversion option and allocated the remaining consideration received for the total convertible loan to the loan component itself, which constitutes the host contract as stated above. This component shall be measured in subsequent periods at amortized cost (using the effective interest method). As part of a valuation performed by management as of the Completion Date, the total consideration received by the Company in 2024 amounting to approximately USD $450 thousand (NIS 1,692 thousand ) was initially allocated to the conversion component and a financial derivative for the conversion mechanism, which constitutes a financial liability measured initially and in subsequent reporting periods at Fair Value Through Profit or Loss, Annex G-47 KADIMASTEM LTD.
NOTES TO FINANCIAL STATEMENTS Note 23: — Events after the reporting date (cont.) in accordance with the provisions of IFRS9, “Financial Instruments”. The remaining amount was allocated to the debt component, which shall be presented at amortized cost at a discount rate of 309%. For the six -monthperiod ended June30, 2024, finance costs (interest and foreign exchange differences) of USD $441 thousand (NIS 1,629 thousand) were recognized for the loan. I. Board Approval of Mr. Ronen Twito Dual Role as CEO and Executive Chairman On October 22, 2024, the Board decided that Mr. Twito would be appointed as the Company’s CEO, replacing Mr. Asaf Shiloni who completed his term as CEO on the same day. Mr. Twito will serve as both the CEO and Executive Chairman, in accordance with Section 121(c) of the Companies Law 1999, pending shareholder approval. The Board supports this decision with the fact that Mr. Twito brings over two decades of executive leadership experience in the biotech and high -techsectors, with an impressive track record of driving corporate growth and shareholder value across NASDAQ and TASE listed companies. J. Merger agreement with NLS On July 28, 2024, the Company entered into a binding letter of intent for a